Just one month after devastating news that its gastroparesis candidate, TZP-102, missed its endpoint in a Phase IIb trial, Tranzyme Pharma Inc., of Research Triangle Park, N.C., reported that its a second Phase IIb trial of the same drug was being discontinued after an interim futility analysis showed a large placebo effect and no treatment effect.